

CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu. India. Phone +91 44 28156653 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

## **PRESS RELEASE**

## CAPLIN POINT LISTED ON FORBES ASIA'S "200 BEST UNDER A BILLION" FOR SECOND CONSECUTIVE YEAR

Chennai, July 02, 2015: For the second consecutive year running, Caplin Point Laboratories Ltd has been selected under Forbes Asia's 200 Best Under a Billion list for 2015. The list has been published in the magazine's July 2015 edition.

Forbes Asia has selected 200 best performing companies, with revenues of less than a billion, from a list of 17,000 public listed companies across the Asia-Pacific. A total of 11 companies have been selected from India, out of which Caplin Point is the only pharmaceutical company to feature on the list in both 2014 and 2015.

"This recognition is a testament to our company's strong performance over the last few years. At Caplin, we're committed to continuing our consistent performance, investment into existing and new facilities and geographies and enriching our shareholders" said Mr.C.C.Paarthipan, Chairman, Caplin Point Laboratories, on the listing.

## **ABOUT CAPLIN POINT LABORATORIES LIMITED:**

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.

Caplin Point has four state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company currently holds over 1600 product licenses across Latin America and Africa with another 400 in the pipeline.

Caplin Point has recently commissioned a state of the art sterile injectable manufacturing facility for catering to regulated markets like US, EU, South Africa and Australia. Caplin Point is in the process of receiving accreditations from various leading Ministry of Health agencies like EU and ANVISA-Brazil. The company will be filing their first ANDAs before the end of 2015.

Company has also recently added Soft Gelatin Capsules, Suppositories and Carbapenem lines to its existing facilities, for emerging markets.

\*\*\*\*\*\*\*\*

